aTyr Pharma, Inc. (ATYR) — Cash Flow-to-Debt Ratio
aTyr Pharma, Inc. (ATYR) has a Cash Flow-to-Debt Ratio of -0.45x as of December 2025, meaning its operating cash flow of $-12.20 Million could theoretically repay 0% of its total liabilities ($26.88 Million) in one year. See how much free cash does aTyr Pharma, Inc. generate to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
aTyr Pharma, Inc. Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for aTyr Pharma, Inc. across 14 annual periods. Also explore aTyr Pharma, Inc. equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for aTyr Pharma, Inc. (2012–2025)
Year-by-year debt coverage analysis for aTyr Pharma, Inc.. For market capitalisation and broader financial context, see aTyr Pharma, Inc. (ATYR) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.31x | $-61.99 Million | $26.88 Million | ▲ +9.9% |
| 2024 | -2.56x | $-69.12 Million | $27.00 Million | ▼ -132.6% |
| 2023 | -1.10x | $-33.22 Million | $30.18 Million | ▲ +35.6% |
| 2022 | -1.71x | $-41.89 Million | $24.50 Million | ▲ +66.9% |
| 2021 | -5.16x | $-33.08 Million | $6.41 Million | ▼ -144.2% |
| 2020 | -2.11x | $-15.30 Million | $7.24 Million | ▼ -60.1% |
| 2019 | -1.32x | $-20.01 Million | $15.16 Million | ▲ +18.9% |
| 2018 | -1.63x | $-31.06 Million | $19.10 Million | ▲ +3.6% |
| 2017 | -1.69x | $-42.36 Million | $25.11 Million | ▲ +43.4% |
| 2016 | -2.98x | $-52.86 Million | $17.72 Million | ▼ -18.5% |
| 2015 | -2.52x | $-36.80 Million | $14.62 Million | ▼ -1130.8% |
| 2014 | -0.20x | $-22.82 Million | $111.65 Million | ▼ -25.0% |
| 2013 | -0.16x | $-17.31 Million | $105.87 Million | ▲ +87.5% |
| 2012 | -1.30x | $-11.38 Million | $8.73 Million | — |